{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-25-000134","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.564638+00:00","generated_at":"2026-05-17T08:52:26.301853+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Editas Medicine nominates EDIT-401 as lead in vivo candidate; ~90% LDL-C reduction in NHPs","bullets":["EDIT-401 achieved ~90% mean LDL-C reduction after single dose in non-human primates across all doses (1.5-4 mg/kg), sustained for one month.","Observed at least 6-fold mean increase in LDLR protein levels; no adverse effects; transient liver enzyme increases resolved within one week.","Plans to submit IND/CTA for EDIT-401 by mid-2026 with human proof-of-concept data targeted by end of 2026.","Company re-confirmed cash runway into Q2 2027 based on existing cash and Vertex payments.","Editas will focus resources on EDIT-401 advancement; intends to identify additional target cell type by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-25-000134","json":"https://secwatch.observer/filing/0001650664-25-000134.json","markdown":"https://secwatch.observer/filing/0001650664-25-000134.md","text":"https://secwatch.observer/filing/0001650664-25-000134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000134/0001650664-25-000134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000134/edit-20250902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:52:26.301853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}